Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia requiring therapy~* Baseline staging requirements~* Absolute Neutrophil Count \> 500/microliter (uL)~* Platelet Count \> 25,000/uL~* Serum creatinine \< 2.5mg/dL~* Total bilirubin and transaminase (SGOT) \< 2.5 X Upper Limit of Normal (ULN)~* Greater than 18 years of age~* Life expectancy of 3 months or greater~* Eastern Cooperative Oncology Group (ECOG) status performance of 0-2~Exclusion Criteria:~* Chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry~* Pregnant or lactating women~* Serious co-morbid disease~* Uncontrolled bacterial, fungal or viral infection~* Active second malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide and Rituximab (Type: EXPERIMENTAL): Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.

Based on this trial design, predict the completion outcome and termination type (if applicable).